Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02591173 · ClinicalTrials.gov registry record · Early Phase 1
Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure
A Early Phase 1 study, sponsored by Vanderbilt University Medical Center.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 7
- Enrollment target
NCT02591173: Clinical Trial Early Phase 1 study, sponsored by Vanderbilt University Medical Center.
NCT02591173 is a Early Phase 1 study that was terminated before completion, run by Vanderbilt University Medical Center. The registered enrollment target is 7 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02591173, a Early Phase 1 study, was terminated before completion, sponsored by Vanderbilt University Medical Center.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
Pharmacologic approaches to increase levels or actions of the vasodilatory peptide angiotensin-(1-7) are currently in development for the treatment of hypertension based on findings from animal models. There are limited and contradictory clinical studies, however, and it is not clear if this peptide regulates blood pressure in humans. The purpose of this study is to better understand the cardiovascular effects angiotensin-(1-7) in human hypertension, and to examine interactions of this peptide with the autonomic nervous system. The investigators propose that the difficulties in showing angiotensin-(1-7) cardiovascular effects in previous clinical studies relates to the buffering capacity of the baroreceptor reflex to prevent changes in blood pressure. Autonomic failure provides the ideal patient population to test this hypothesis. These patients have loss of baroreflex buffering and have low levels of angiotensin-(1-7) in blood. The investigators will test if angiotensin-(1-7) infusion can lower blood pressure in patients with autonomic failure, and will determine the hemodynamic and hormonal mechanisms involved in this effect.
Primary Outcome
The decrease in blood pressure following angiotensin-(1-7) versus saline infusion.
Interventions
- DRUG Saline
- DRUG Angiotensin-(1-7)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-02 |
| Est. Completion | 2020-07 |
| Phase | Early Phase 1 |
Why NCT02591173 stopped before completion
NCT02591173 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT02591173 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02591173 about?
NCT02591173 is a clinical study titled "Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure". Pharmacologic approaches to increase levels or actions of the vasodilatory peptide angiotensin-(1-7) are currently in development for the treatment of hypertension based on findings from animal models. There are limited and contradictory clinical studies, however, and it is not clear if this peptide...
What is the current status of trial NCT02591173?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 7 participants. The study started on 2016-02. Estimated completion is 2020-07.
What interventions are being tested in trial NCT02591173?
The interventions under investigation include: Saline (DRUG), Angiotensin-(1-7) (DRUG).
Who is sponsoring clinical trial NCT02591173?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02591173's enrollment target sits among peer trials
7 1825th of 2000 higher than 156 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia